Physician profile
Marina Su
NPI 1184972648
$4,217.30
in general payments reported to CMS, 2019-2025
22 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $131 · 2021: $14.00 · 2022: $639 · 2023: $237 · 2024: $733 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,019.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $693.54 | 2019-2023 | |
| Rxsight INC | $292.44 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alcon Vision LLC | $289.54 | 2019-2025 | Rocklatan, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $257.29 | 2019 | |
| Bausch & Lomb Americas INC. | $252.86 | 2024 | Miebo, Xiidra, Infuse |
| Biotissue Holdings INC. | $180.85 | 2019-2024 | |
| Coopervision INC. | $167.50 | 2022-2024 | Paragon Crt |
| Alexion Pharmaceuticals, INC. | $124.99 | 2022 | |
| Dompe US, INC. | $123.89 | 2022 | |
| Amgen INC. | $117.56 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $116.64 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $105.93 | 2022 | |
| Abbvie INC. | $89.91 | 2023-2025 | Lumigan, Vuity, Alphagan P |
| Johnson & Johnson Vision Care, INC. | $79.54 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $74.91 | 2019 | |
| Harrow Eye, LLC | $56.37 | 2025 | Vevye |
| Shire North American Group INC | $47.55 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $41.38 | 2025 | |
| Mallinckrodt Enterprises LLC | $40.12 | 2019 | |
| Synergeyes, INC. | $24.99 | 2019 | |
| Thea Pharma INC. | $19.55 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.